Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
91.36 CHF | -0.73% | -2.93% | +7.39% |
27/05 | Novartis: positive phase III results in C3G | CF |
27/05 | Novartis: presented results for kidney disease | CF |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.39% | 21TCr | |
+38.43% | 73TCr | |
-7.08% | 35TCr | |
+17.11% | 33TCr | |
+0.59% | 28TCr | |
+14.15% | 24TCr | |
-5.97% | 20TCr | |
+4.84% | 16TCr | |
-1.79% | 16TCr | |
-0.75% | 12TCr |
- Stock Market
- Equities
- NOVN Stock
- News Novartis AG
- NOVARTIS AG : UBS reiterates its Neutral rating